Pharmacopsychiatry 2012; 45(06): 236-240
DOI: 10.1055/s-0032-1301884
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Tolerability of Switching to Ziprasidone in Italian Patients with Acute Exacerbation of Schizophrenia: An Open-Label Trial

C. Mencacci
1  Fatebenefratelli Hospital, Milan, Italy
on behalf of all investigators› Author Affiliations
Further Information

Publication History

received 07 December 2010
revised 08 November 2011

accepted 11 January 2012

Publication Date:
16 May 2012 (eFirst)



The long-term maintenance of a stable condition is an important aim of schizophrenia therapy, which frequently requires the switch between 2 antipsychotic agents. This 8-week multicenter study, conducted in Italy, evaluates the switch from a previous antipsychotic to ziprasidone.


Adult acute schizophrenic patients requiring a change in antipsychotic for lack of efficacy or tolerability issues took ziprasidone 20 − 80 mg/bid. Dosages could be adjusted during the study. The primary efficacy outcomes were the differences in positive and negative syndrome scale (PANSS) and clinical global impression severity (CGI-S) scores from baseline to study end. Other efficacy variables were clinical global impression improvement, global assessment of functioning, patient preference scale and drug attitude inventory.


189 patients were evaluated; the mean (±SD) ziprasidone dose was 95.9±34.5 mg/day. PANSS and CGI-S scores significantly decreased throughout the study. All secondary outcomes significantly improved at the end of the study vs. baseline values. Ziprasidone was well tolerated; 13 patients reported a QTc prolongation (mild in 12 patients).


Notwithstanding the limitations of any non-comparative study, these results suggest that ziprasidone may be an effective and well-tolerated option in acute schizophrenia patients who discontinued a previous antipsychotic agent.